The Latest Breaking News from FDA

Mark Cuban’s prescription drug company, known for “cutting out the middle man,” is in conversations with hospitals around the nation to identify the most common drug shortages.

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

Two deaths linked to the drug may present a more complicated path to approval.

The advent of vaping revived nicotine addiction among young people after a dramatic decline. The FDA seems poised to at last yank some products aimed at teens from the market. Will it work?

Amid prevalent COVID-19 cases, vaccine pioneer Pfizer (PFE) is significantly benefiting. Moreover, the company beat wall street expectations in the third quarter with a robust financial result and raised its revenue and EPS guidance for the year. Given its strong fundamentals, the stock could be a wise addition to your…

The National Vaccine Institute (NVI) plans to use locally developed Covid-19 vaccines as booster shots when they are completed and approved by the Food and Drug Administration (FDA).

As the Fed’s aggressive monetary policy resulted in slightly cooled inflation last month, investors are hopeful of smaller rate hikes ahead. However, since a recession is expected to hit the economy next year, we think fundamentally sound stocks Pfizer (PFE), Flowers Foods (FLO), and Xperi (XPER), which are rated Strong…